Giuseppe Gritti

15PUBLICATIONS
74CO-AUTHORS
Oncology and carcinogenesis not elsewhere classifiedHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Electrochemical energy storage and conversion
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 16, 2026
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.

|Jun 22, 2026
Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series.

|Apr 22, 2026
Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

|Jan 28, 2026
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Eva Domingo-Domènech, Barbara Pro, Tim Illidge

|Oct 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Martin Hutchings, Anna Sureda, Francesc Bosch

|Aug 01, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Eva Domingo-Domènech, Barbara Pro, Tim Illidge

Pageof 3

Frequent Collaborators

5 joint publications

Alessandro Rambaldi

4 joint publications

Pier Luigi Zinzani

3 joint publications

Steven M Horwitz

3 joint publications

Federico Lussana